News

Juvenescence is encouraged by Forbes’ recent article, highlighting the exponential nature in which scientific breakthroughs are occurring in anti-aging research. The fundamental biological processes that lead to aging are being increasingly understood, due to the convergence of scientific knowledge with…...

Juvenescence, a life sciences company utilising expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, is pleased to announce the successful closure of its $100 million Series…...

Juvenescence is encouraged by Bank of America Merrill Lynch’s recent report, ‘Immortal combat – Future Human Primer’, where their analysts have highlighted the impending growth of longevity-focused companies. They estimate that the market for ‘techmanity’, technology to increase human lifespan,…...

Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. As a new division of the company, Juvenescence Life is focused on the commercialization of scientifically proven and branded health supplements, nutraceuticals, and medical foods…...

Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration. Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of…...

As part of the 'Beyond 100' programme from November 2018, Barclays released a video discussing the science of longevity and the implications of living until 120. Jim Mellon, chairman of Juvenescence, discusses in the video how science is elucidating the…...

Juvenescence announces that David Ellam has joined its Executive Management Team as Chief Financial Officer. David has almost 20 years of experience within life science companies. He has previously occupied several senior finance roles within both US & UK publicly…...

Juvenescence is pleased to announce its latest equity investment in BYOMass Inc., a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases. Juvenescence will provide BYOMass with up to $6.5 million in equity…...

Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics, Ltd, a joint venture. The company will focus on novel approaches to inducing a state of ketosis, which may have protective…...

Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million. Juvenescence intends to complete its $100 million Series B financing with the closing of a second tranche in…...

Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, Ltd to develop drugs against a novel aging-related target. The Buck Institute is one of the leading research centers in the…...

Juvenescence has successfully raised $50 million in its Series A financing. The Series A financing was oversubscribed with participation from founders, insiders, institutional investors and family offices. Jim Mellon, of Juvenescence Limited said: “We are delighted with the progress we…...